Assistance Fund: Acute Myeloid Leukemia

Not Funded
About
The Assistance Fund: Acute Myeloid Leukemia program offers crucial financial support for individuals diagnosed with acute myeloid leukemia. Utilizing drugs such as Neupogen, Cytarabine, and Venclexta, this program assists with copays, coinsurance, deductibles, as well as other out-of-pocket expenses for eligible patients. By ensuring access to FDA-approved treatments and offering both copay and financial assistance, the Assistance Fund: Acute Myeloid Leukemia program aims to alleviate the financial burden on patients. Re-enrollment is required annually to continue receiving benefits.
Insurance requirements: Commercially insured, Medicare / Medicaid
Enrollment Forms
Enrollment Form
Program Requirements
Valid only for residents in the US and Puerto Rico
Enrollment Required: Yes
Coverage Required: No
Needs Based: Yes
Activation Required: No
Program Details
Please note the following:
1. Copay grant programs provide assistance for copays, coinsurance, and deductibles for FDAapproved treatment for the disease named in the disease program ONLY
2. Financial assistance grant programs provide assistance for other eligible outofpocket costs, such as health insurance premiums and incidental medical expenses, in addition to copay, coinsurance, and deductible assistance on FDAapproved treatment for the disease named in the disease program
3. This fund may cover offlabel drugs
Copay and Financial assistance can be utilized by any innetwork pharmacy or site of care able to dispense the medication or provide treatment
Program offers conditional approval of 30 days of immediate assistance for open programs where funding is available
Patients will be asked to provide and verify demographic, insurance, and financial information (additional documentation may be requested)
Approved patients will be granted assistance through the end of the calendar year unless otherwise specified for the applicable program
Other Programs

Assistance Fund: Acute Myeloid Leukemia: Waitlist

Commercially Insured
Medicare / Medicaid

CancerCare: Myelodysplastic Syndromes

Commercially Insured
Medicare / Medicaid
Max Saving: $10000/year*
Other Tools for Vyxeos